drugset
drugset / Trial / NCT02034227

Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia

NCT02034227 ↗

Phase 1/2 Terminated 6 enrolled Spirogen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did not work, whose cancer came back or who are not candidates for other types of standard therapy.

Timeline

Start
2012-04
Primary completion
2014-06
Completion
2014-06

Drugs

EvaluationDrugModalityDoseRoute
Subject SJG-136 Small molecule 15 ug/m2 Intravenous
Subject SJG-136 Small molecule 30 ug/m2 Intravenous

Indications

acute myeloid leukemia chronic lymphocytic leukemia/small lymphocytic lymphoma